Plus Therapeutics, Inc

Plus Therapeutics (Nasdaq: PSTV) is a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for adults and children with rare and difficult-to-treat cancers. Our lead drug candidate, Rhenium-186 Nanoliposome, is being evaluated in the NIH-supported multi-center ReSPECT clinical trials for patients with recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer

Nanotechnology,oncology,cancer,liposome,drug delivery,lung cancer,breast cancer,ovarian cancer,nanomedicine,healthcare,innovation,growth,nasdaq,brain cancer,glioblastoma,rare disease,liver cancer,radioembolization,radiopharmaceutical,and pstv

Plus therapeutics, inc operates in the Pharmaceutical manufacturing industry.

Plus therapeutics, inc's revenue is 1m - 10m

Plus therapeutics, inc has 11 - 50 employees.